Browsing by author "Lewis, Rebecca"
Now showing items 21-29 of 29
-
RE-ARMing the Immune Response to Bladder Cancer with Radiotherapy.
Wilkins, A; Hall, E; Lewis, R; Gribble, H; Melcher, A; et al. (ELSEVIER SCIENCE LONDON, 2022-07-01) -
Recognising the challenges of implementing multi-centre adaptive plan of the day radiotherapy.
Webster, A; McNair, HA; Hansen, VN; Lewis, R; Patel, E; et al. (Elsevier BV, 2022-03-01)Two multicentre adaptive radiotherapy trials utilising Plan of the Day (PoD) with a library of plans were introduced in 35 centres. The common issues that arose from all centres when introducing PoD were collated ... -
Study within a trial of electronic versus paper-based Patient-Reported oUtcomes CollEction (SPRUCE): study protocol for a partially randomised patient preference study.
Philipps, L; Foster, S; Gardiner, D; Gath, J; Gillman, A; et al. (BMJ PUBLISHING GROUP, 2023-09-21)INTRODUCTION: Patient-reported outcomes (PRO) are currently collected from trial participants using paper questionnaires by the Clinical Trials and Statistics Unit at The Institute of Cancer Research (ICR-CTSU). Streamlining ... -
The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis.
Cullen, M; Huddart, R; Joffe, J; Gardiner, D; Maynard, L; et al. (ELSEVIER, 2019-11-26)BACKGROUND: Standard management in the UK for high-risk stage 1 nonseminoma germ cell tumours of the testis (NSGCTT) is two cycles of adjuvant bleomycin, etoposide (360 mg/m2), and cisplatin (BE360P) chemotherapy, or ... -
The Development of Therapeutic Radiographers in Imaging and Adaptive Radiotherapy Through Clinical Trial Quality Assurance.
Webster, A; Hafeez, S; Lewis, R; Griffins, C; Warren-Oseni, K; et al. (ELSEVIER SCIENCE LONDON, 2021-03-22)AIMS: Adaptive radiotherapy (ART) is an emerging advanced treatment option for bladder cancer patients. Therapeutic radiographers (RTTs) are central to the successful delivery of this treatment. The purpose of this work ... -
The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial.
Lewis, R; Todd, R; Newton, M; Jones, RJ; Wilson, C; et al. (BMC, 2020-07-08)BACKGROUND: The utility of patient screening logs and their impact on improving trial recruitment rates are unclear. We conducted a retrospective exploratory analysis of screening data collected within a multicentre ... -
The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011).
Moynihan, C; Lewis, R; Hall, E; Jones, E; Birtle, A; et al. (2012-11-29)Background Evidence suggests that poor recruitment into clinical trials rests on a patient 'deficit' model - an inability to comprehend trial processes. Poor communication has also been cited as a possible barrier to ... -
The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).
Choudhury, A; West, CM; Porta, N; Hall, E; Denley, H; et al. (ELSEVIER SCI LTD, 2017-02-28)BACKGROUND: Severe chronic hypoxia is associated with tumour necrosis. In patients with muscle invasive bladder cancer (MIBC), necrosis is prognostic for survival following surgery or radiotherapy and predicts benefit from ... -
Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL).
Dearnaley, D; Griffin, CL; Lewis, R; Mayles, P; Mayles, H; et al. (ELSEVIER SCIENCE INC, 2019-03-01)PURPOSE: To establish the toxicity profile of high-dose pelvic lymph node intensity-modulated radiation therapy (IMRT) and to assess whether it is safely deliverable at multiple centers. METHODS AND MATERIALS: In this phase ...